Search results
Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
GuruFocus.com via Yahoo Finance· 2 months agoExelixis Inc. (NASDAQ:EXEL) is a pharmaceutical company headquartered in Alameda, California that...
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
Zacks via Yahoo Finance· 5 months agoIt was a busy week for the biotech sector, with numerous study readouts and other updates. Quite a...
Life Expectancy After Kidney Removal
Verywell Health via Yahoo News· 3 months agoWhat does long-term survival depend on? A nephrectomy (kidney removal surgery) is a major surgery that has risks and requires several weeks or longer to...
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
Zacks via Yahoo Finance· 8 months agoBased on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically...
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
Zacks via Yahoo Finance· 7 months agoThe FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg...
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
Zacks via Yahoo Finance· 5 months agoExelixis, Inc. EXEL entered into a clinical collaboration with clinical-stage company Arcus...
Signs and Symptoms of Kidney Cancer
Health via Yahoo News· 5 days agourbazon / Getty Images Medically reviewed by Gagandeep Brar, MD Your kidneys remove waste products from your blood and flush out toxins from your body through your urine. These internal organs ...
Is Kidney Cancer Curable? Understanding the Odds
Verywell Health via Yahoo News· 3 months agoThere are several types of kidney (renal) cancer. Each type is potentially curable if it's found and treated early, before the cancer has a chance to...
Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo...
Benzinga via Yahoo Finance· 1 year agoBristol Myers Squibb & Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced three-year follow-up...
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
Zacks via Yahoo Finance· 2 years agoExelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with...
